DIVIDEND. AMENDMENT TO BYLAWS

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) (“Genomma Lab” or “the Company”) announces the following matters that will be submitted to the consideration of the Annual Ordinary and Extraordinary Shareholders’ Meeting of Genomma Lab Internacional, S.A.B. de C.V. (the “Company”):

1. The approval to pay a dividend, in cash, to the Company’s shareholders up to the amount of $800,000,000 Mexican Pesos, in the dates and terms of payment to be determined by the Shareholders’ Meeting;

2. Proposal to amend the Company's bylaws:
   
   (i) articles eighth and fifteenth of the Company's bylaws, in order to change the form on which the calls to shareholders meetings and notices regarding capital increases will be published, in order to adequate the Company’s bylaws to the new provisions of the General Law of Commercial Companies (Ley General de Sociedades Mercantiles); and

   (ii) article twenty seventh of the Company’s bylaws, in order to provide for the possibility that the audit committee and the corporate practices committee may be integrated in a single committee, as provided in the Securities Market Law.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low - cost, highly flexible supply chain operating model.

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.